Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 3Phase 3 2Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Patient Preference 1

Interventions

Cytarabine 6Thioguanine 4Methotrexate 4Idarubicin 4Etoposide 4Daunorubicin 4Azacitidine 4Peripheral Blood Stem Cell Transplantation 3Early Intervention, Educational 3Decitabine 3Cyclophosphamide 3liposomal amphotericin B 2decitabine and cedazuridine drug combination 2Therapeutics 2Radiotherapy 2Psychiatric Rehabilitation 2ON 01910 2Mitoxantrone 2Hydrocortisone 2Filgrastim 2Dexamethasone 2Busulfan 2Biopsy 2Asparaginase 2valspodar 1sabatolimab 1pevonedistat 1palmitoyl-L-asparaginase 1merphos 1lonafarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Myelomonocytic, Chronic × decitabine and cedazuridine drug combination × Clear all
NCT05883956 2025-03-20

PREFER-HMA

Otsuka Australia Pharmaceutical Pty Ltd

Phase 3 Active not recruiting
13 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference

NCT03306264 2024-08-27

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Astex Pharmaceuticals, Inc.

Phase 3 Completed
227 enrolled 37 charts 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡